Regulus Therapeutics (RGLS) Q2 Revenue Tops Views

Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.41), may not compare to the analyst estimate of ($0.29). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $2.4 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• O'Reilly Automotive (ORLY) Misses Q1 EPS by 7c, Offers Guidance
• Universal Health Realty (UHT) Reports Q1 EPS of $0.38